**Core tip:** Post-transplant lymphoproliferative disorder (PTLD) is one of the complications that may occur after liver transplantation. The present study is a survival analysis of liver transplant patients after PTLD development. The incidence of PTLD was 6.25% in pediatric patients and 1.18% in adult liver transplant recipients. The main new finding is association of serum tacrolimus level with post-PTLD survival. Higher serum tacrolimus level was associated with lower post-PTLD survival in pediatric patients.

INTRODUCTION
============

Liver transplantation is an established modality of treatment for end-stage liver diseases of various etiologies. Despite considerable improvement in outcomes of patients, complications frequently occur after transplantation that may have negative impact on survival\[[@B1]\]. Post-transplant lymphoproliferative disorder (PTLD) is one of the complications that may occur after liver transplantation and threatens both graft and patient survival. PTLD is generally believed to be a consequence of relative immunodeficiency state secondary to immunosuppressive regimens in these patients\[[@B2]\]. Immunosuppressive therapy results in depressed T-cell function that predisposes patients to lymphoid proliferation\[[@B3]\]. Epstein-Barr virus (EBV) infection is the other major risk factor for development of PTLD after liver transplantation and the majority of cases (60%-70%) are EBV-positive\[[@B4]\]. While EBV infection has minimal consequences in normal subjects, in liver transplant recipients it is associated with a spectrum of disorders, ranging from reactive monoclonal hyperplasia to aggressive malignant lymphoma\[[@B5]\]. In immunocompetent subjects, the EBV genome remains latent in resting memory B cells after immortalization\[[@B6]\]. However, after transplantation, long-term immunosuppressive therapy results in depressed T-cell function and lack of T-cell inhibition on B-cell proliferation\[[@B7]\]. This may lead to uncontrolled B-cell proliferation and subsequent hyperplasia, and even malignant transformation.

PTLD is more frequently encountered in pediatric patients, and younger age by itself is a known risk factor for PTLD despite controversies\[[@B8]\]. Another proposed risk factor for PTLD development after liver transplantation is hepatitis C virus infection\[[@B9]\]. With a mortality rate ranging from 12% to 60% in different studies, PTLD has imposed considerable negative impact on transplant patients until recently\[[@B10]-[@B12]\]. However, outcomes of patients and survival rates have been substantially improved by using new modalities for treatments, such as rituximab (a chimeric anti-CD20 monoclonal antibody) and sirolimus, in addition to reduced-dose immunosuppression\[[@B13]-[@B15]\].

This study aimed to investigate incidence, risk factors (including impact of immunosuppressive regimen) and survival of PTLD patients after liver transplantation in Iranian patients.

MATERIALS AND METHODS
=====================

Patients
--------

Shiraz Organ Transplant Center (Shiraz, Iran) is a leading transplant center in Iran, with considerable annual cases of liver transplantation for both adult and pediatric patients. A cross-sectional survey was conducted among the adult and pediatric patients (\< 18 years) who underwent liver transplantation at Shiraz Transplant Center between August 2004 and March 2015. Clinical and laboratory data of patients were collected using a data gathering form containing information regarding age, sex, underlying liver disease, type of allograft (deceased donor, living related donor, split liver transplantation), time of liver transplantation and time of PTLD development, survival of patients from date of liver transplantation, survival after PTLD diagnosis, immunosuppressive regimen and dosage, rejection episodes, EBV status before and after transplantation, presenting sign and symptoms, PTLD histology, multi-organ involvement, modality of treatment, response to therapy, and serum level of calcineurin inhibitors (including tacrolimus and cyclosporine). All patients received intravenous methylprednisolone as induction of immunosuppression. Patients received tacrolimus, cyclosporine, mycophenolate mofetil and prednisolone as immunosuppressive therapy during their follow-up. Serum tacrolimus level was measured periodically during follow-up for each patient and the last measured serum tacrolimus levels before diagnosis of PTLD were recorded and analyzed for each patient. Patients were treated with rituximab or chemotherapy based on grade, type and invasiveness of PTLD. Change from tacrolimus to sirolimus was applied for all of the patients diagnosed with PTLD. Thirteen patients with positivity for cytomegalovirus (CMV)-DNA were treated with ganciclovir or valganciclovir.

PTLD diagnosis
--------------

Diagnosis of PTLD was confirmed by tissue biopsies reviewed by expert pathologists. World Health Organization (WHO) classification for tumors of lymphoid tissue was used for PTLD classification\[[@B16]\]. While diagnosis of PTLD was confirmed, patients underwent staging work-up, including CT scans (abdomen, chest and pelvis) and bone marrow aspiration and biopsy to detect possibility of multiple organ involvement. Frozen section or paraffin immunoperoxidase staining or flow cytometry were applied for immunophenotyping of B-cell- and T-cell-associated antigens, as previously described.

Whether PTLD is monoclonal or polyclonal was determined by flow cytometry on fresh cell suspensions checking immunoglobulin light chain restriction, by immunoperoxidase staining on frozen or paraffin-embedded tissues or by southern blot on frozen tissues checking immunoglobulin or T-cell receptor gene rearrangements\[[@B17]\].

Based on these classification, one patient had nodular sclerosis Hodgkin disease, one had plasmacytoma, and others had polymorphic and monomorphic B cell lymphoma.

Ethics and consent
------------------

The study protocol was approved by the institutional review board of Shiraz University of Medical Sciences. The study protocol was carried out in accordance with the Helsinki Declaration as revised in Seoul 2008. Written informed consent was obtained from patients.

Statistical analysis
--------------------

Comparisons of continuous variables were performed with the Student's *t*-test, and categorical variables were compared using the chi-square test. Non-parametric Mann-Whitney test was used when appropriate. Data were presented using mean ± standard deviation for numeric variables, and percent and counts for categorical variables. Kaplan-Meier estimates were used for analysis of time to PTLD development and survival after PTLD diagnosis. Kaplan-Meier and Cox regression analyses were used to calculate the influence of probable risk factors on PTLD development and survival. Rejection episodes were considered a time varying statistical variable, and rejections that occurred after PTLD development were excluded. Statistical analysis was performed with SPSS 16.0 (SPSS Inc., Chicago, IL, United States). A *P* value of \< 0.05 were considered statistically significant.

RESULTS
=======

PTLD characteristics and post-PTLD survival
-------------------------------------------

Overall, 53 patients were diagnosed with PTLD. There were 40 cases of PTLD in the pediatric age group and 13 cases in the adult group. The incidence of PTLD was 6.25% in the pediatric patients and 1.18% in the adult liver transplant recipients. The baseline characteristics of PTLD patients are outlined in Table [1](#T1){ref-type="table"}.

###### 

Baseline characteristics of patients

                                 **Pediatrics**   **Adults**   **Overall**
  ------------------------------ ---------------- ------------ ---------------
  Number                         40               13           53
  Mean age in years              5.05 ± 4.43      42 ± 13.39   14.11 ± 17.71
  Sex, male/female               23/17            10/3         33/20
  Allograft                                                    
  Living donor                   28               0            28
  Deceased donor                 12               13           25
  Presenting sign and symptoms                                 
  LAP                            18               9            27
  Fever                          13               1            14
  Abdominal pain                 15               3            18
  Diarrhea                       5                0            5
  Weight loss                    0                1            1
  Cough and dyspnea              1                0            1
  Bowel obstruction              1                0            1
  Unilateral weakness            1                0            1
  Underlying liver disease                                     
  HBV cirrhosis                  0                5            5
  Cryptogenic cirrhosis          0                2            2
  PSC                            0                2            2
  HCV cirrhosis                  0                1            1
  AIH                            2                1            3
  Wilson's disease               1                0            1
  PFIC                           5                0            5
  Crigler-Najjar syndrome        8                0            8
  Biliary atresia                12               0            12
  Tyrosinemia                    10               0            10
  Budd-Chiari syndrome           1                1            2
  Liver metastasis               0                1            1
  Neonatal hepatitis             1                0            1
  Immunosuppressive regimen                                    
  Prednisolone                   39               12           49
  Tacrolimus                     36               10           46
  Mycophenolate mofetil          15               11           26
  Cyclosporine                   1                4            5
  Sirolimus                      35               8            43

AIH: Autoimmune hepatitis; LAP: Lymphadenopathy; HBV: Hepatitis B virus; HCV: Hepatitis C virus; PFIC: Progressive familial intrahepatic cholestasis; PSC: Primary sclerosing cholangitis.

The mean overall (adult and pediatric) post-PTLD survival was 66.29 ± 11.86 mo. The post-PTLD survival of patients at 6 mo was 75.1% ± 6%, at 1 year was 68.9% ± 6.5% and at 5 years was 39.2% ± 14.2% (Figure [1A](#F1){ref-type="fig"}).

![Post-transplant lymphoproliferative disorder survival. A: Pediatric and adult patients; B: Adult patients; C: Pediatric patients. PTLD: Post-transplant lymphoproliferative disorder.](WJG-23-1224-g001){#F1}

The mean post-PTLD survival in adult patients was 82.94 ± 18.58 mo. The post-PTLD survival of adult patients at 6 mo was 83.9% ± 10.4%, at 1 year was 74.6% ± 12.8% and at 5 years was 59.7% ± 16.8% (Figure [1B](#F1){ref-type="fig"}).

The mean post-PTLD survival in pediatric patients was 42.61 ± 6.1 mo. The post-PTLD survival of pediatric patients at 6 mo was 72.4% ± 7.1%, at 1 year was 67.1% ± 7.5% and at 5 years was 24.1% ± 18.6% (Figure [1C](#F1){ref-type="fig"}).

When both pediatric and adult patients were analyzed altogether, multi-organ involvement was significantly associated with lower post-PTLD survival (104.25 ± 9.08 mo *vs* 27.13 ± 6.30 mo, *P* = 0.002) (Figure [2A](#F2){ref-type="fig"}). EBV-positive patients with PTLD had significantly higher mean survival compared to EBV-negative PTLD patients (60.58 ± 7.62 mo *vs* 16.72 ± 5.66 mo, *P* = 0.018) (Figure [2B](#F2){ref-type="fig"}). Other variables including sex, CMV status, rejection episodes, time to PTLD before or after 1 year, and type of allograft had no significant effect on post-PTLD survival (Table [2](#T2){ref-type="table"}).

###### 

Kaplan-Meier analysis of risk factors and post-transplant lymphoproliferative disorder survival of pediatric and adult patients

                                      **Mean survival in mo**   ***P* value**
  ----------------------------------- ------------------------- ---------------
  Sex                                                           0.902
  Male                                65.65 ± 13.18             
  Female                              36.06 ± 5.30              
  Multi-organ involvement                                       0.002
  (+)                                 27.13 ± 6.30              
  (-)                                 104.25 ± 9.08             
  CMV status                                                    0.370
  CMV-positive                        51.98 ± 10.50             
  CMV-negative                        23.29 ± 5.76              
  EBV status                                                    0.002
  EBV-positive                        60.58 ± 7.62              
  EBV-negative                        16.72 ± 5.66              
  Rejection episode                                             0.762
  (+)                                 64.90 ± 13.78             
  (-)                                 65.86 ± 15.76             
  Time to PTLD development in years                             0.704
  ≤ 1                                 62.18 ± 14.03             
  ≥ 1                                 75.13 ± 12.49             
  Type of allograft                                             0.904
  Living donor                        50.56 ± 6.95              
  Deceased donor                      60.32 ± 14.33             

CMV: Cytomegalovirus; EBV: Epstein-Barr virus; PTLD: Post-transplant lymphoproliferative disorder.
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We also analyzed the influence of different risk factors on pediatric PTLD patients separately. Multi-organ involvement and EBV negativity were significantly associated with lower mean post-PTLD survival in pediatric patients (Table [3](#T3){ref-type="table"}). Higher serum tacrolimus level was associated with lower post-PTLD survival in pediatric patients (OR = 1.07, 95%CI: 1.006-1.15, *P* = 0.032) (Table [4](#T4){ref-type="table"}).

###### 

Kaplan-Meier analysis of risk factors and post-transplant lymphoproliferative disorder survival of pediatric patients

                                      **Mean survival in mo**   ***P* value**
  ----------------------------------- ------------------------- ---------------
  Sex                                                           0.749
  Male                                41.41 ± 7.38              
  Female                              35.85 ± 5.76              
  Multi-organ involvement                                       0.002
  (+)                                 25.82 ± 6.90              
  (-)                                 67.62 ± 5.56              
  CMV status                                                    0.139
  CMV-positive                        58.82 ± 9.56              
  CMV-negative                        19.35 ± 6.21              
  EBV status                                                    0.002
  EBV-positive                        60.58 ± 7.62              
  EBV-negative                        5.58 ± 2.72               
  Rejection episode                                             0.888
  (+)                                 43.61 ± 8.49              
  (-)                                 36.02 ± 5.24              
  Time to PTLD development in years                             0.326
  ≤ 1                                 39.72 ± 6.86              
  ≥ 1                                 36.45 ± 5.30              
  Type of allograft                                             0.806
  Living donor                        50.56 ± 6.95              
  Deceased donor                      37.37 ± 8.11              

CMV: Cytomegalovirus; EBV: Epstein-Barr virus; PTLD: Post-transplant lymphoproliferative disorder.

###### 

Cox regression analysis showing association of different risk factors and post-transplant lymphoproliferative disorder survival of pediatric patients

                           **Mean**   **OR**   **95%CI**    ***P* value**
  ------------------------ ---------- -------- ------------ ---------------
  Age in years             5.05       0.94     0.82-1.08    0.434
  Time to PTLD in months   15.63      0.96     0.91-1.02    0.242
  Tacrolimus level         14.99      1.07     1.006-1.15   0.032
  Tacrolimus dose          3.81       1.06     0.67-1.66    0.797
  Prednisolone dose        10.12      0.99     0.86-1.13    0.897

PTLD: Post-transplant lymphoproliferative disorder.

Impact of multi-organ involvement, and time to PTLD development
---------------------------------------------------------------

Patients were divided into those who developed PTLD in ≤ 1 year and those who developed PTLD in ≥ 1 year. Age, post-PTLD survival, serum tacrolimus level, tacrolimus dose and prednisolone dose were not correlated with time to PTLD development in pediatric patients (*P* \> 0.05) (Table [5](#T5){ref-type="table"}). However, multi-organ involvement was more common in patients who developed PTLD within 1 year after liver transplantation (*P* = 0.007) (Table [6](#T6){ref-type="table"}). Multi-organ involvement was also more common in pediatric patients who developed PTLD within 1 year after liver transplantation (*P* = 0.007) (Table [6](#T6){ref-type="table"}).

###### 

Influence of different continuous variables on time to post-transplant lymphoproliferative disorder development, mortality and multi-organ involvement of post-transplant lymphoproliferative disorder patients

                       **Mean rank PTLD development ≤ 1 yr**   **Mean rank PTLD development ≥ 1 yr**   ***U* value**   ***Z* score**   ***P* value**
  -------------------- --------------------------------------- --------------------------------------- --------------- --------------- ---------------
  Age                  19.85                                   21.85                                   158             -0.50           0.61
  Post-PTLD survival   20.19                                   21.15                                   167             -0.24           0.80
  Tacrolimus level     16.57                                   14.61                                   86              -0.54           0.58
  Tacrolimus dose      19.84                                   18.85                                   154             -0.27           0.78
  Prednisolone dose    20.56                                   18.88                                   154             -0.44           0.65
                       Alive patient                           Deceased patient                                                        
  Age                  23.19                                   16.47                                   127.5           -1.78           0.74
  Tacrolimus level     13.62                                   21.00                                   55              -2.11           0.03
  Tacrolimus dose      18.96                                   20.43                                   175             -0.40           0.68
  Prednisolone dose    19.65                                   20.57                                   171             -0.25           0.79
  Mean time to PTLD    23.12                                   16.56                                   129             -1.74           0.08
                       Multi-organ (+)                         Multi-organ (-)                                                         
  Age                  19.50                                   19.50                                   176             0.00            1.00
  Tacrolimus level     16.50                                   14.74                                   97              -0.54           0.58
  Tacrolimus dose      20.27                                   18.14                                   146             -0.60           0.54
  Prednisolone dose    19.81                                   19.27                                   171             -0.15           0.87
  Post-PTLD survival   15.59                                   22.34                                   113             -1.85           0.06
  Mean time to PTLD    13.62                                   23.77                                   82              -2.78           0.005

PTLD: Post-transplant lymphoproliferative disorder.

###### 

Influence of different risk factors on time to post-transplant lymphoproliferative disorder development

                            **PTLD development ≤ 1 yr**   **PTLD development ≥ 1 yr**   ***P* value**
  ------------------------- ----------------------------- ----------------------------- ---------------
  All PTLD patients                                                                     
  Sex                                                                                   0.150
  Male                      17                            16                            
  Female                    14                            6                             
  Multi-organ involvement                                                               0.007
  (+)                       15                            3                             
  (-)                       14                            18                            
  CMV status                                                                            0.186
  CMV-positive              9                             4                             
  CMV-negative              11                            1                             
  EBV status                                                                            0.296
  EBV-positive              12                            5                             
  EBV-negative              8                             1                             
  Rejection episode                                                                     0.399
  (+)                       15                            9                             
  (-)                       16                            13                            
  Mortality                                                                             0.324
  (+)                       13                            7                             
  (-)                       18                            15                            
  Type of allograft                                                                     0.118
  Living donor              19                            9                             
  Deceased donor            12                            13                            
  Pediatric PTLD patients                                                               
  Sex                                                                                   0.496
  Male                      15                            8                             
  Female                    12                            5                             
  Multi-organ involvement                                                               0.018
  (+)                       14                            2                             
  (-)                       11                            11                            
  CMV status                                                                            0.368
  CMV-positive              9                             3                             
  CMV-negative              9                             1                             
  EBV status                                                                            0.184
  EBV-positive              12                            5                             
  EBV-negative              6                             0                             
  Rejection episode                                                                     0.587
  (+)                       13                            6                             
  (-)                       14                            7                             
  Mortality                                                                             0.120
  (+)                       13                            3                             
  (-)                       14                            10                            
  Type of allograft                                                                     0.609
  Living donor              19                            9                             
  Deceased donor            8                             4                             

CMV: Cytomegalovirus; EBV: Epstein-Barr virus; PTLD: Post-transplant lymphoproliferative disorder.

Multi-organ involvement was associated with increased mortality after PTLD development (*P* \< 0.05) (Table [7](#T7){ref-type="table"}). EBV-positive patients with PTLD had lower mortality when compared to EBV-negative patients (*P* \< 0.05) (Table [7](#T7){ref-type="table"}).

###### 

Influence of different risk factors on mortality after post-transplant lymphoproliferative disorder

                            **Alive patient**   **Deceased patient**   ***P* value**
  ------------------------- ------------------- ---------------------- ---------------
  All PTLD patients                                                    
  Sex                                                                  0.491
  Male                      10                  13                     
  Female                    13                  7                      
  Multi-organ involvement                                              0.001
  (+)                       6                   12                     
  (-)                       26                  6                      
  CMV status                                                           0.284
  CMV-positive              9                   4                      
  CMV-negative              6                   6                      
  EBV status                                                           0.042
  EBV-positive              13                  4                      
  EBV-negative              3                   6                      
  Rejection episode                                                    0.600
  (+)                       15                  9                      
  (-)                       18                  11                     
  Type of allograft                                                    0.485
  Living donor              18                  10                     
  Deceased donor            15                  10                     
  Pediatric PTLD patients                                              
  Sex                                                                  0.424
  Male                      13                  10                     
  Female                    11                  6                      
  Multi-organ involvement                                              0.001
  (+)                       5                   11                     
  (-)                       19                  3                      
  CMV status                                                           0.110
  CMV-positive              9                   3                      
  CMV-negative              4                   6                      
  EBV status                                                           0.018
  EBV-positive              13                  4                      
  EBV-negative              1                   5                      
  Rejection episode                                                    0.525
  (+)                       11                  8                      
  (-)                       13                  8                      
  Type of allograft                                                    0.309
  Living donor              18                  10                     
  Deceased donor            6                   6                      

CMV: Cytomegalovirus; EBV: Epstein-Barr virus; PTLD: Post-transplant lymphoproliferative disorder.

Multi-organ involvement was not associated with age, serum tacrolimus level, tacrolimus dose, prednisolone dose in univariate analysis (Table [5](#T5){ref-type="table"}). EBV-positive patients were less likely to have multi-organ involvement in comparison with EBV- negative patients (*P* = 0.008) (Table [8](#T8){ref-type="table"}). Pediatric patients who received liver allograft from deceased donors were more likely to develop PTLD with multi-organ involvement when compared to those receiving liver allograft from living donors (*P* = 0.019) (Table [8](#T8){ref-type="table"}).

###### 

Influence of different risk factors on multi-organ involvement in patients with post-transplant lymphoproliferative disorder

                           **Multi-organ involvement (+)**   **Multi-organ involvement (-)**   ***P* value**
  ------------------------ --------------------------------- --------------------------------- ---------------
  All PTLD patients                                                                            
  Sex                                                                                          0.421
  Male                     12                                19                                
  Female                   6                                 13                                
  CMV status                                                                                   0.418
  CMV-positive             6                                 7                                 
  CMV-negative             7                                 5                                 
  EBV status                                                                                   0.008
  EBV-positive             5                                 11                                
  EBV-negative             8                                 1                                 
  Rejection episode                                                                            0.448
  (+)                      9                                 14                                
  (-)                      9                                 18                                
  Type of allograft                                                                            0.235
  Living donor             8                                 19                                
  Deceased donor           10                                13                                
  Pediatric PTL patients                                                                       
  Sex                                                                                          0.206
  Male                     11                                11                                
  Female                   5                                 11                                
  CMV status                                                                                   0.335
  CMV-positive             5                                 7                                 
  CMV-negative             6                                 4                                 
  EBV status                                                                                   0.006
  EBV-positive             5                                 11                                
  EBV-negative             6                                 0                                 
  Rejection episode                                                                            0.520
  (+)                      8                                 10                                
  (-)                      8                                 12                                
  Type of allograft                                                                            0.019
  Living donor             8                                 19                                
  Deceased donor           8                                 3                                 

CMV: Cytomegalovirus; EBV: Epstein-Barr virus; PTLD: Post-transplant lymphoproliferative disorder.

Estimation of a cutoff value for tacrolimus level in pediatric patients
-----------------------------------------------------------------------

To estimate a cutoff point value for tacrolimus level in relation to post-PTLD survival in pediatric patients, we used receiver operating characteristic (ROC) curve analysis. A serum tacrolimus of over 11.1 ng/mL was predictive of post-PTLD survival (sensitivity = 90%, specificity = 52%, area under the curve = 0.738, *P* = 0.035).

DISCUSSION
==========

The present study is one of the largest series of patients with PTLD after liver transplantation. Our study showed that the incidence of PTLD following pediatric liver transplantation was much higher than for adult liver transplantation (6.25% in pediatrics and 1.18% in adults). While previous studies reported PTLD incidence of up to 20% after pediatric liver transplantation\[[@B18]\], recent reported incidence from different studies are lower and range from 10% to 5.5%\[[@B19],[@B20]\]. Since PTLD is mainly considered as a result of interaction of immunosuppression and EBV infection, the decreased incidence in pediatric patients may be secondary to the better monitoring of patients, especially for immunosuppressive regimen and EBV infection. In pediatric patients, our reported incidence is comparable to other studies; however, due to unexplained reasons the incidence of PTLD after adult liver transplantation in our study was lower than previous reports from other centers\[[@B21]\].

Mean post-PTLD survival was higher in the adult patients than in the pediatric patients. This observation is probably due to the long-term survival (\> 10 years) of 2 of our adult patients. In a recent study conducted in our center, the 1-year and 5-year overall survival of pediatric liver transplant recipients was found to be 73% and 66% respectively\[[@B22]\]. In this way, the 1-year post-PTLD survival in the pediatric age group is nearly equal to the overall survival of our pediatric patients. However, it should be noted that the 5-year post-PTLD survival in pediatric patients has dramatically declined to 24.1%.

Due to small numbers of adult PTLD patients, the analyses were performed on either pediatric patients or adult plus pediatric patients. We investigated the impact of different variables on post-PTLD survival. As expected, multi-organ involvement was associated with a lower post-PTLD survival and increased mortality. EBV-positive patients had higher mean post-PTLD survival in comparison with EBV-negative subjects. EBV positivity was also associated with lower mortality, especially among the pediatric age group. These findings may be jeopardized by our other finding that EBV-positive patients had lower probability of multi-organ involvement.

Although up to 30% of PTLD patients are EBV-negative, EBV has been generally considered as responsible for most cases of PTLD. However, the influence of recipient EBV status on outcomes of PTLD patients is conflicting. Some studies have shown that EBV-negative PTLD patients have more malignant appearing disease with an aggressive course and higher mortality rate\[[@B23],[@B24]\]. In univariate analysis, our findings are inconsistent with these mentioned results. However, in regression analysis, EBV status was not associated with post-PTLD survival. Several other studies showed that EBV status had no significant impact on outcomes of PTLD patients, including their survival\[[@B25]-[@B28]\]. EBV status was not associated with time of PTLD development in our study. This finding is in contrast with previous reports showing that EBV-negative PTLD occurs later after liver transplantation when compared to EBV-positive PTLD patients\[[@B29],[@B30]\].

Immunosuppressive therapy has been reported to be associated with PTLD development. Treatment of rejection episodes with steroid or OKT3 were risk factors of PTLD development, especially during 1 year after treatment\[[@B31],[@B32]\]. Reducing dose of immunosuppressive medications is another treatment strategy used on PTLD patients in some studies\[[@B33],[@B34]\]. In our study, rejection episode, steroid dose and tacrolimus dose were not associated with PTLD survival, while higher serum tacrolimus level was associated with lower survival. Finally, we showed that a serum tacrolimus cutoff value of over 11.1 ng/mL is associated with post-PTLD survival, having a high sensitivity but a rather low specificity in pediatric patients. Therefore, it might be suggested that transplant physicians consider adjustment of tacrolimus dose to maintain its serum level around this cutoff point.

Although a PTLD series has been published from our center previously\[[@B35]\], this study is the first that evaluates incidence, survival and associated factors influencing survival of PTLD patients after liver transplantation. This study is also the first that shows the association between serum tacrolimus level and post-PTLD survival, and suggests a serum tacrolimus cutoff point value to adjust tacrolimus dose.

COMMENTS
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Background
----------

Post-transplant lymphoproliferative disorder (PTLD) is one of the complications after liver transplantation and may threaten both graft and patient survival. This study aimed to investigate incidence and survival of PTLD patients after liver transplantation.

Research frontiers
------------------

Few studies with considerable number of patients have reported survival of PTLD patients after liver transplantation. This study aimed to investigate incidence, risk factors (including impact of immunosuppressive regimen) and survival of PTLD patients after liver transplantation in Iranian patients.

Innovations and breakthroughs
-----------------------------

Multi-organ involvement was associated with a lower post-PTLD survival and increased mortality. Epstein-Barr virus (EBV)-positive patients had higher mean post-PTLD survival in comparison with EBV-negative subjects. EBV status was not associated with time of PTLD development in our study. This finding is in contrast with previous reports showing that EBV-negative PTLD occurs later after liver transplantation when compared to EBV-positive PTLD patients. We showed that a serum tacrolimus cutoff value of 11.1 ng/mL is associated with post-PTLD survival.

Applications
------------

Adjustment of tacrolimus level to lower than 11.1 ng/mL may help improve post-PTLD survival of patients.
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